ALLOB Shows 90% Fusion Rate at 2 Years in Phase IIa Study
90% of patients show bone fusion as well as strong clinical improvements in function and pain at 24 months follow-up with a good product safety profile.
Empowering Orthopaedic Executives through Strategic Intelligence
Aziyo Biologics Announces Pricing of Initial Public Offering
The company's FiberCel, ViBone and OsteGro V viable bone matrices address orthopedic and spine applications.
Graftys Gains CE Recertification of Bone Void Fillers
Graftys' products are registered in more than 30 countries worldwide, including Europe, the U.S., Canada and South America.
Biologica Technologies Launches OsseoGEN Cellular Bone Matrix
OsseoGEN CBM contains the three elements needed for bone regeneration; osteoconductivity, osteoinductivity and osteogenicity.
Artoss Hits Record Sales of NanoBone Bone Graft
NanoBone bone grafting material incorporates nano-crystalline hydroxyapatite particles that are similar in size, chemistry and morphology to HA particles of human bone.
Bone Therapeutics Collaborates on ALLOB in Asia
Bone Therapeutics granted an exclusive license to develop and collaborate on ALLOB in Greater China and a number of other major Asian countries.
MagnetOs Bone Grafts Approved in Australia
MagnetOs Granules and MagnetOs Putty received TGA approval in Australia. Initial market launch is scheduled for late 1Q21.
Seikagaku Signs Marketing Agreement for OA Treatment
Eisai and Seikagaku will co-develop and market the SI-613 sodium hyaluronate therapeutic agent in South Korea for the treatment of knee osteoarthritis.
Spine Wave Launches Tornado Bioactive Bone Graft Matrix
Tornado synthetic and bioactive bone graft alternative is delivered to the surgical site safely and quickly using the GraftMag Graft Delivery System.
Bioventus Reaches Milestone with DUROLANE Worldwide
DUROLANE injection treats knee osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacological therapy or analgesics.
M&A | Partnerships
Bone Therapeutics Collaborates on ALLOB in Asia
Bone Therapeutics granted an exclusive license to develop and collaborate on ALLOB in Greater China and a number of other major Asian countries.
Seikagaku Signs Marketing Agreement for OA Treatment
Eisai and Seikagaku will co-develop and market the SI-613 sodium hyaluronate therapeutic agent in South Korea for the treatment of knee osteoarthritis.
Royal Biologics Acquires FIBRINET Platelet-Rich Fibrin Matrix
Fibrinet enables safe and rapid preparation of Platelet-Rich Fibrin Membrane and Platelet-Rich Fibrin Gel from a small sample of blood at the point of care.
Products
ALLOB Shows 90% Fusion Rate at 2 Years in Phase IIa Study
90% of patients show bone fusion as well as strong clinical improvements in function and pain at 24 months follow-up with a good product safety profile.
Aziyo Biologics Announces Pricing of Initial Public Offering
The company's FiberCel, ViBone and OsteGro V viable bone matrices address orthopedic and spine applications.
Biologica Technologies Launches OsseoGEN Cellular Bone Matrix
OsseoGEN CBM contains the three elements needed for bone regeneration; osteoconductivity, osteoinductivity and osteogenicity.
Regulatory
Graftys Gains CE Recertification of Bone Void Fillers
Graftys' products are registered in more than 30 countries worldwide, including Europe, the U.S., Canada and South America.
MagnetOs Bone Grafts Approved in Australia
MagnetOs Granules and MagnetOs Putty received TGA approval in Australia. Initial market launch is scheduled for late 1Q21.
Cerapedics Gains Canadian Approval of Next-Gen Bone Graft
Canada will be the first commercial market to launch i-FACTOR+ Matrix. The technology is currently being studied in an FDA IDE trial targeting lumbar fusion.